Keryx Biopharmaceuticals (Keryx Biopharmaceuticals) Altman Z-Score : -8.01 (As of Apr. 26, 2024)

Keryx Biopharmaceuticals Altman Z-Score Chart

Keryx Biopharmaceuticals Annual Data
	Trend	Dec08	Dec09	Dec10	Dec11	Dec12	Dec13	Dec14	Dec15	Dec16	Dec17
Altman Z-Score		Get a 7-Day Free Trial					29.55	16.30	-2.27	-7.38	-8.01

Keryx Biopharmaceuticals Quarterly Data
	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18
Altman Z-Score	Get a 7-Day Free Trial															-6.46	-8.01	-9.90	-7.79	-7.95

Competitive Comparison of Keryx Biopharmaceuticals's Altman Z-Score

For the Biotechnology subindustry, Keryx Biopharmaceuticals's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Keryx Biopharmaceuticals's Altman Z-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Keryx Biopharmaceuticals's Altman Z-Score distribution charts can be found below:

* The bar in red indicates where Keryx Biopharmaceuticals's Altman Z-Score falls into.

Keryx Biopharmaceuticals Altman Z-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Keryx Biopharmaceuticals's Altman Z-Score for today is calculated with this formula:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.

Trailing Twelve Months (TTM) ended in Sep. 2018:
Total Assets was $151.78 Mil.
Total Current Assets was $126.41 Mil.
Total Current Liabilities was $57.10 Mil.
Retained Earnings was $-1,058.33 Mil.
Pre-Tax Income was -16.995 + -21.518 + -22.53 + -30.724 = $-91.77 Mil.
Interest Expense was -0.144 + -1.367 + 0 + -62.965 = $-64.48 Mil.
Revenue was 28.036 + 25.749 + 21.751 + 18.682 = $94.22 Mil.
Market Cap (Today) was $404.46 Mil.
Total Liabilities was $206.00 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

The zones of discrimination were as such:

Distress Zones - 1.81 < Grey Zones < 2.99 - Safe Zones

Keryx Biopharmaceuticals has a Altman Z-Score of -8.01 indicating it is in Distress Zones.

Study by Altman found that companies that are in Distress Zone have more than 80% of chances of bankruptcy in two years.

Keryx Biopharmaceuticals  (NAS:KERX) Altman Z-Score Explanation

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.

X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.

Read more about Altman Z-Score and the original research.

Be Aware

Altman Z-Score does not apply to financial companies.

Keryx Biopharmaceuticals Altman Z-Score Related Terms

Thank you for viewing the detailed overview of Keryx Biopharmaceuticals's Altman Z-Score provided by GuruFocus.com. Please click on the following links to see related term pages.

Keryx Biopharmaceuticals (Keryx Biopharmaceuticals) Business Description